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Dengue virus (DENV) and Chikungunya virus (CHIKV) are arboviruses that share the same Aedes mosquito vectors and thus
overlap in their endemic areas. These two viruses also cause similar clinical presentations, especially in the initial stages of infection,
with neither virus possessing any specific distinguishing clinical features. Because the outcomes and management strategies for these
two viruses are vastly different, early and accurate diagnosis is imperative. Diagnosis is also important for surveillance, outbreak
control, and research related to vaccine and drug development. Available diagnostic tests are aimed at detection of the virus, its
antigenic components, or the host immune antibody response. In this review, we describe the recent progress and continued
challenges related to the diagnosis of DENV and CHIKV infections.

1. Introduction
Dengue virus (DENV) and Chikungunya virus (CHIKV) are
single-stranded, positive-sense RNA viruses. DENV belongs
to the family Flaviviridae and genus Flavivirus of which there
are 5 known serotypes (DENV1–5). CHIKV belongs to the
family Togaviridae and genus Alphavirus of which there are
3 known strains (Asian-West African; East-Central; South
African) [1]. The genome of each virus is approximately
11 kb in length [1, 2]. The DENV genome encodes three
structural (C, prM, and E) and seven nonstructural (NS1,
NS2B, NS3, NS4A, NS4B, and NS5) proteins [3]. The CHIKV
genome encodes three structural (C, E1, and E2) and four
nonstructural (nsP1–4) proteins [1].
Both viruses are arthropod-borne viruses (arboviruses)
sharing a common vector: mosquitos of the Aedes genus,
specifically A. aegypti and A. albopictus [4]. Both viruses circulate in similar geographic regions. In nonendemic regions,
travel-associated infections are an important consideration
for patients with a recent travel history who present with
fever. Concurrent infection with both viruses, transmitted
from either two different mosquitos or one dually infected
mosquito, is possible [5, 6]. For DENV, transmission has also
been reported to occur via infected blood products, organ

donation, and prenatal and/or perinatal vertical transmission
[7].
While DENV and CHIKV present similarly as an acute
febrile illness, these two viruses have vastly different management strategies and outcomes. The majority of CHIKV
infections are self-limiting with chronic joint disease being
the most common long-term outcome, and fatality is exceedingly rare. Nonsteroidal anti-inflammatory drugs (NSAIDs)
are the mainstay treatment for CHIKV, but NSAIDs should
be avoided until DENV is confidently ruled out, as NSAIDs
are contraindicated in DENV infection [8]. DENV is likewise commonly a self-limiting illness, yet this diagnosis
necessitates stricter monitoring due to the potential for
more significant morbidity and mortality. Infection with one
serotype of DENV confers lifelong immunity to that particular serotype but only short-term immunity to the other
serotypes; subsequent infections with a different serotype
increase the risk of severe complications [7].

2. Epidemiology
The majority of DENV and CHIKV infections affect people
residing in endemic areas, which include most of the tropical
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and subtropical regions in the world. Many of these areas
serve as popular tourist destinations and, consequently,
dengue-related infections have recently surpassed malaria
and gastrointestinal infections as the most common cause
of fever among travelers [23]. The major endemic regions
include Southeast Asia, the Western Pacific, the Eastern
Mediterranean, Africa, and the Americas [9]. Specific countries with cocirculation and coinfections of DENV and
CHIKV include India, Sri Lanka, Gabon, Cameroon, Madagascar, Indonesia, Singapore, and Thailand [24]. In the
United States, autochthonous outbreaks of DENV have been
reported in Hawaii and along the Texas-Mexico border, and
outbreaks of both DENV and CHIKV have recently occurred
in southwest Florida [6, 25].

3. Clinical Presentation
These two viruses share a similar geographic distribution;
unfortunately, their clinical manifestations also show substantial overlap. The typical incubation periods for DENV
and CHIKV are 4–7 days and 3–7 days, respectively [4].
Patients infected with either virus typically present with acute
onset of fever, myalgia, and headache, and some patients
experience a maculopapular rash and/or gastrointestinal
symptoms [4, 6].
A classification scheme for DENV, put forth by the
World Health Organization (WHO) in 2009, includes criteria
for probable dengue and severe dengue [9]. Most DENV
infections are either asymptomatic or mild and self-limited,
but there are “warning signs” that may suggest which patients
may progress to severe disease and require stricter medical
management [9]. Severe dengue may manifest as significant
plasma leakage, hemorrhagic complications, and/or severe
organ impairment, so early recognition of DENV infection
is imperative [9]. Compromising the sensitivity of the WHO
classification scheme is the fact that patient age influences the
type and severity of symptoms; Low et al. found that fewer
older adults reported symptoms of myalgia and arthralgia,
as well as mucosal bleeding, which is one of the primary
“warning signs” [26].
The clinical course for CHIKV is likewise typically mild
and self-limited. The hallmark presentation of CHIKV is a
bilateral migratory arthralgia, often intense, affecting mainly
the small joints of the extremities [1, 4]. However, most
children with CHIKV report only mild arthralgia [8]. The
major long-term complication is persistence of joint pain
and stiffness, which may last years after resolution of the
initial infection [1]. Rarely, CHIKV infection is associated
with neurologic, ophthalmologic, and hemorrhagic disease
[4, 5].
While neither infection possesses a defining clinical
feature, there are suggested trends in the symptomatology
and complete blood count (CBC) results that may help
differentiate between the two infectious processes. It is
suggested that, at initial presentation, significantly more
DENV patients have thrombocytopenia (platelets < 100 ×
109 /L) and associated minor bleeding complications such as
petechiae and nose bleeds, while patients with CHIKV are
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more likely to have arthralgia. Leukopenia is common to
both infections at initial presentation but tends to be more
pronounced in DENV patients; CHIKV patients tend to have
higher white blood cell (WBC) counts (>3.6 or 5.0 × 109 /L
according to two separate authors) than DENV patients [4,
6, 8]. During the course of illness, DENV patients are more
likely to have abdominal pain and the CBC will demonstrate
leukopenia, neutropenia, and thrombocytopenia that is more
frequent and more pronounced than in CHIKV patients.
In contrast, CHIKV patients may show a shorter duration
of fever, conjunctivitis, acute arthritis, and more prominent
arthralgia affecting multiple joints [6]. While these trends in
clinical findings may be helpful, they are neither specific nor
consistent enough to be considered diagnostic.
Unfortunately, there is no single clinical or laboratory
marker available for distinguishing DENV or CHIKV infection from each other or from other acute febrile illnesses.
Therefore, both of these viruses must be initially included in
the differential diagnosis for a patient with suspicious clinical
symptoms who is living in or returning from travel to an
endemic area. Clinical features can serve, at best, as a guide
for favoring one virus over the other, as patients may present
atypically, either by lacking the “classic” signs or symptoms
as mentioned above, or by presenting in an uncharacteristic
manner. Laboratory diagnostic tests are thus essential for
accurate identification of the causative virus.

4. Methods for Diagnosis
A wide variety of laboratory diagnostic methods are available
to aid in the diagnosis of DENV and CHIKV infections.
The premise of these tests is detection of the virus, viral
components (antigens or nucleic acid), or the host immunologic response to the virus [10]. Therefore, selection and
interpretation of testing depends on the kinetics of viremia
and antibody response, which differ between primary and
secondary infections. Other factors influencing test choice
include the purpose of testing and availability of resources.
Each type of test offers unique advantages and disadvantages,
and a combination of tests may be employed in order to
increase diagnostic confidence. For a summary of available
tests for DENV and CHIKV infection, see Tables 1 and 2,
respectively.
4.1. Overview of Currently Available Tests. The acute febrile
phase of infection corresponds to the period of viremia,
which lasts typically from 5 days after onset of fever for both
DENV and CHIKV. During this time, diagnosis rests on
isolation of the virus, viral RNA, or viral antigen from the
specimen. Isolation of DENV or CHIKV can be performed
via mosquito inoculation or cell culture; CHIKV isolation
can also be accomplished by intracerebral inoculation of mice
[16]. Virus may be recovered from serum, plasma, whole
blood, or tissues collected at autopsy. Mosquito inoculation
is the most sensitive isolation method but is impractical for
routine diagnosis due to the highly specialized requirements
and high maintenance costs [3]. Cell culture is in wider use,
with preference given to the mosquito cell line C6/36 (cloned

NS1 detection via
ELISA

Detection of viral
antigen

Detection of host
antibody response

IgA

IgM/IgG ratio
Serum and saliva

Serum

93 (serum);
70–92 (saliva)

61.5–99

MAC-ELISA

IgG ELISA

98.5

Serum, plasma, whole
blood, fresh or FFPE
tissues, urine, and
saliva

88 (serum);
97 (saliva)

79.9–97.8

100

71–80 (serum);
100 (CSF, if
neurological
symptoms)
100
100

54.2–93.4 (serum);
73.9–76.9 (urine)
50 (CSF, if neurological
symptoms)
48.4–98.2
58.9–100

Serum, urine, and CSF

100

71.5–84.2 (mosquito
inoculation);
40.5 (cell line-based)

Serum, plasma, whole
blood, and fresh or
FFPE tissues

Specificity (%)

Disadvantages
Technical, laborious
Greatest specificity
Variable sensitivity
Allows for further characterization of
Narrow window of
isolate
detection (viremic period)
Does not differentiate
Early diagnosis
between serotypes
Rapid tests available
Lower sensitivity in
secondary infections
Rapid turnaround time
Expensive reagents and
Multiplex available (can identify all
specialized equipment
serotypes from single sample; less
potential for contamination)
Does not require specialized
equipment (i.e., thermocyclers)
Cross-reactivity among
serotypes (not
Detection of IgM is considered
serotype-specific) and with
diagnostic
other flaviviruses
(false-positives)
Can distinguish primary from
Later diagnosis (need
secondary infection using paired sera postconvalescent sample)
Distinguishes between primary from
Later diagnosis
secondary infection
Option for testing saliva (easier
Lower sensitivity in
sample to obtain)
primary infection
Better sensitivity and specificity in
secondary infection

Advantages

Table 1: Diagnostic tests for DENV infection.
Sensitivity (%)

Sample types

Isothermal
amplification methods
(NASBA, LAMP)

RT-PCR
Real-time RT-PCR

Virus isolation

Detection of virus

Detection of viral
nucleic acid

Method

Premise of test

[3, 9, 14, 15]

[3, 9, 14]

[11–13]

[3, 9, 10]

References
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ELISA or
immunochromatographic assay
(ICA)

Detection of
viral antigen

Detection of
host antibody
response

Detection of
viral nucleic
acid

Virus isolation (in
vivo or in vitro)

Detection of
virus

Sensitivity (%)

Serum

Serum

PRNT

Serum
CSF

Serum and dried
blood spots

Serum and CSF

85–97

90–98

Expensive reagents and
specialized equipment

Expensive reagents and
specialized equipment
[13, 16, 18–20]

Disadvantages
References
Technical, laborious
Requires biosafety level 3
[1]
containment
May take 1-2 weeks
Commercial assays not widely
available
[16, 17]
Requires biosafety level 3
containment

Possible cross-reactivity with
other alphaviruses
Elevated IgM does not
distinguish recent past
infection from acute infection
Lack the ability to quantify
[4, 16, 17, 20–
Sensitive and specific
antibodies, are subjective, and 22]
Commercially available
require special equipment and
training
Very specific for alphaviruses;
Requires the use of live virus
gold standard for confirmation of (requires Biosafety level 3
serologic test results
containment)
Widely available
Relatively cheaper and easier to
perform
IgG: 53 (serum)
Rapid bedside tests are available
IgM: 95 (serum)

IgM: 17 (serum); 48
(CSF)
IgG: 45 (serum); 63
(CSF)

Does not require specialized
equipment (i.e., thermocyclers)

Multiplex available

Highly sensitive and specific
Rapid turnaround time
Multiplex available

Early diagnosis

Highly specific

Advantages

95.25

Up to 100

Up to 100

89 (serum)
87 (CSF)

100

Specificity (%)

100

100

100

85 (serum)
80 (CSF)

Serum, plasma,
whole blood, and
Variable
fresh or FFPE tissues

Sample types

IFA

ELISA

Isothermal
amplification
methods (RT-LAMP)

Real-time RT-PCR

RT-PCR

Diagnostic method

Premise

Table 2: Diagnostic tests for CHIKV infection.
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from A. albopictus) or AP61 (cloned from A. pseudoscutellaris) [9, 16]. Other less sensitive options include mammalian
cell cultures such as Vero, LLC-MK2, and BHK-21 [3]. The
resultant virus isolate may be further characterized during
subsequent in vitro studies, such as genome sequencing, virus
neutralization, and infection studies [3]. Virus isolation is
highly specific and has a theoretical detection limit of a
single viable virus, although, in practice, the sensitivity is
only approximately 40.5% in cell line-based virus isolation.
It also requires highly trained operators, a dependence on
sample integrity and a short viremia period, thus providing a narrow window of opportunity from illness onset.
Virus isolation followed by an immunofluorescence assay
for confirmation requires days to weeks [9, 16]. Therefore,
despite its advantages, this approach is not widely used in
routine diagnostic laboratories and may serve more use in
surveillance purposes. A more recent development in viral
isolation is described by Patramool et al., who used anionic
polymer-coated beads to isolate DENV and CHIKV [27].
This may prove a useful strategy to monitor the status of
circulating mosquitos in regions at risk for outbreaks with
these arboviruses. Compared to traditional isolation techniques, this method provides reduced cost, good sensitivity,
and rapidity, which is conducive to simultaneous analysis of
a large number of samples [27].
Compared to virus isolation, viral nucleic acid detection
techniques performed on acute-phase specimens offer better
sensitivity with a much more rapid turnaround time. Viral
nucleic acid can be detected for a few additional days beyond
the period of viremia. Detection of viral nucleic acid can
be accomplished by reverse transcriptase polymerase chain
reaction (RT-PCR), real time RT-PCR, or isothermal amplification methods. All of these methods involve three basic
steps: viral RNA extraction, amplification, and detection and
characterization of the amplified product [9]. There is a wide
variety of specimen types that can be tested with RT-PCR,
including blood, serum, plasma, and fresh or formalin-fixed
paraffin-embedded tissues. For DENV, urine and saliva have
been found to be suitable specimen types as well [3]. Testing
urine samples by real-time RT-PCR provides a larger window
of detection that extends well past the viremia period; DENV
RNA may be detected in urine up to day 16, compared to day 8
for blood specimens [28]. The ability to test urine and saliva is
advantageous in patients for whom blood samples are difficult
to obtain, such as in newborns and patients with hemorrhagic
syndromes [14].
RT-PCR using primers designed for structural and nonstructural domains has been found to be useful in the rapid
diagnosis of CHIKV. The combination of RT-PCR/nested
PCR has proved efficient for specific detection and genotyping of CHIKV. Loop-mediated isothermal amplification
(LAMP) assays can be rapidly carried out at a single temperature in a water bath, with visually detectable results, and
comparable sensitivities to conventional PCR [17].
Detection of viral antigens is another diagnostic methodology available for DENV infection. Nonstructural protein 1
(NS1) antigen is a highly conserved glycoprotein produced
during the virus replication process, and a soluble form of
NS1 accumulates in high concentrations in the serum of

5
patients with both primary and secondary DENV infections
[29, 30]. Several commercial assays, consisting of both rapid
tests and enzyme-linked immunosorbent assay (ELISA) kits,
are available for the detection of the NS1 antigen. Serum
is the most common sample type. DENV NS1 can also
be detected in urine samples during the acute phase of
DENV infection, which provides an opportunity for the
development of a rapid noninvasive test [11]. Lastly, NS1
antigen may be detected in the cerebrospinal fluid (CSF) of
patients with neurological symptoms [12]. A downfall is that
these tests do not differentiate between dengue serotypes,
as NS1 is highly conserved by all serotypes. Additionally,
these tests are most successful during the acute phase of
illness and lose sensitivity once the period of viremia ends.
The sensitivity of NS1 has also been found to be lower in
DENV secondary infections, which is thought to be due to
assay interference by anti-NS1 antibodies which are present
more frequently in secondary infections [10, 29]. An antigenbased commercial detection assay is not widely available for
CHIKV, and the ones described thus far in the literature have
unclearly established performance characteristics [21, 22].
After the period of viremia, the methods described thus
far become much less sensitive for diagnosis. At this point,
the best diagnostic strategy entails detection of antibodies
indicative of host immune response to the virus. However,
the caveat is that individuals in endemic areas often have
immunologic levels to these viruses. Serologic methods
include ELISA, indirect immunofluorescence assays (IFA),
hemagglutination inhibition (HI), and microneutralization
(MNt) [1]. ELISA and IFA are rapid and sensitive techniques
for detecting virus-specific antibodies and can distinguish
between IgG and IgM. For techniques that cannot make this
distinction (HI and MNt), it is required to compare paired
serum samples (acute and convalescent phases) to establish
recent infection.
For DENV, serologic methods are most commonly
employed, in particular IgM capture ELISA [4]. IgM antibodies are detectable in 50% by days 3–5 after onset, 80%
by day 5, and 99% by day 10 after initial symptoms. They
may persist for months; hence DENV IgM antibodies are a
reliable marker of recent but not necessarily acute infection
[29]. IgG antibody response develops a few days after the
onset of IgM antibodies, and IgG may persist for many years
[29]. Serologic confirmation of infection requires demonstration of a fourfold rise in antibody titer between acute
and convalescent phase sera, or by demonstration of IgM
antibodies specific for the virus [16]. Patterns of antibody
response differ between primary and secondary infections,
with primary dengue invoking stronger and more specific
IgM response than in secondary, which have stronger and
more rapid IgG response. Prior vaccination against other
Flavivirus (Japanese encephalitis virus; Yellow-fever virus)
or prior infection with nondengue flaviviruses (including
West Nile) can potentially influence antibody responses
measured in some assays [4]. The recent introduction of rapid
diagnostic kits that offer combined detection of NS1 and
IgM/IgG antibodies was an effort to create a point-of-care
test with better performance characteristics [13]. Evaluation
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of some of these combined tests has revealed diagnostic
sensitivity of 89–93% and specificity of 75–100% [3, 13].
A combination of molecular and IgM antibody detection
assays is recommended for diagnosis of CHIKV infection.
Some advocate adopting an algorithmic approach, wherein
the IgM capture ELISA is used as an initial screening tool
followed by the use of rapid molecular assays in CHIKV
IgM negative samples, to facilitate rapid diagnosis during
outbreaks [18].
4.2. Simultaneous Testing for DENV and CHIKV. Because
infection with DENV and CHIKV should be on the differential diagnosis together at the initial patient presentation,
tests that screen for these viruses simultaneously are preferred
to test for them separately. CHIKV and DENV are not
readily differentiated serologically due to cross-reactivity of
their serocomplexes, so there is a reliance on molecular
detection methods for this purpose [19]. A one-step duplex
conventional RT-PCR assay for distinguishing DENV and
CHIKV has been reported [20]. Saha et al. developed a highly
sensitive and specific, rapid one-tube duplex RT-PCR assay
which provides a result within 110 minutes [19]. Two authors
have described a one-step multiplex real-time RT-PCR assay
that can simultaneously detect and quantitate RNA for all
DENV serotypes and CHIKV. Cecilia et al. report a sensitivity
of 100% for DENV and 95.8% for CHIKV, while the specificity
was 100% for both viruses when compared to conventional
RT-PCR [24]. Pongsiri et al. report an assay sensitivity of
97.65% and specificity of 92.59% when compared to conventional RT-PCR [31]. Real-time reverse transcription-loopmediated isothermal amplification (RT-LAMP) is a sensitive
alternative to real-time PCR for use in field applications
[18]. A RT-LAMP method has been described in which a
reverse transcription and amplification was designed in one
step with two tubes under the same reaction conditions for
the rapid identification and quantitative detection of RNA
for CHIKV and DENV, respectively [32]. This assay has a
sensitivity of 100% and specificity of 95.25%. The LAMP
reaction can be ended within one hour under isothermal
conditions and does not require sophisticated instruments,
making this method adaptive to field diagnosis. Additionally,
the use of a turbidimeter allows for quantitative detection of
viral load [32]. For RT-PCR assays described above, the onestep process reduces the chance of contamination and there is
lack of cross-reactivity between related Flavivirus groups and
DENV [19].
4.3. Sending Out Samples. Within the United States, CHIKV
testing is performed at the Centers for Disease Control and
Prevention (CDC), a limited number of select state health
departments, and one commercial laboratory. The CDC’s
Arbovirus Diagnostic Laboratory at the Division of VectorBorne Diseases (DVBD) is located in Fort Collins, CO. Test
results are normally available 4 to 14 days after specimen
receipt, but reporting times may be longer during summer
months when arbovirus activity increases. Initial serological
testing is performed using IgM capture ELISA and IgG
ELISA. If the initial results are positive, further confirmatory
testing is performed which may delay the reporting of final
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results. All results are sent to the appropriate state health
department.
The CDC Dengue Branch, located in San Juan, Puerto
Rico, provides DENV testing free of charge to submitting
physicians and state and private laboratories. A “Dengue
Case Investigation Form” must accompany the specimen.
One potentially problematic issue with sending samples to
this laboratory is that an international shipping license is
required. Another challenge, especially for underdeveloped
countries, is specimen preservation during shipment. The
CDC recommendation is that the serum specimen is frozen
immediately after separation and sent on dry ice, or alternatively kept refrigerated and sent in cold packs.
4.4. Future Test Developments. Other diagnostic methodologies may be available for future use in the laboratory diagnosis
of DENV and CHIKV infection. One technique becoming
an increasingly popular serological option in arbovirology is
microsphere-based immunoassay (MIA). This technology is
based on detection by flow cytometry of antigen or antibody
attached to microspheres or beads. This is a much more
rapid test than MAC-ELISA and also has the potential for
performance in multiplex [33]. Similarly, microarray technology, which focuses on detection of nucleic acid fragments
corresponding to different pathogens, is useful to screen
a sample for the many pathogens on a wide differential
diagnosis for infectious symptoms in a given region [10].
Finally, mass spectrometry could be applied to this field
of diagnosis, proving especially useful in determining viral
serotypes and genotypes during an outbreak [9].

5. Conclusion
Confirmation of DENV or CHIKV infection requires laboratory diagnosis. Molecular assays are more sensitive for
diagnosis in the early stages of illness (2–5 days after onset)
when antibodies are not detected. However, in the later stages
of illness, the sensitivity of molecular methods decreases due
to the onset of a brisk immune response and corresponding
reduction in viral load. At this stage, the IgM ELISA is a more
sensitive diagnostic test.
An ideal diagnostic test meets certain key criteria: affordability by those at risk of infection, specificity, sensitivity,
ease of use, rapid results, little reliance on equipment, and
delivery to those in need [29]. The ideal test should also
be part of a multiplexed assay for other pathogens causing
acute undifferentiated fever, such as malaria [17]. Progress
for DENV and CHIKV diagnostic testing has been made.
Generally, tests with high sensitivity and high specificity
require more complex technologies and technical expertise,
while rapid tests may sacrifice sensitivity and specificity for
the advantages of speed and ease of performance. It is difficult
to find a balance between accessibility of a diagnostic method
and the confidence in the test results. Antigen detection
assays seem most promising for rapid and early diagnosis in
rural areas. In this regard, development of DENV diagnostic
tests is ahead of those for CHIKV, but clearly both of these
arboviruses are important causes of disease in their shared
endemic regions and in travelers to these areas.
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